Drug Index

Rituximab

 
print

Mechanism :

The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.


Indication :

• Refractory autoimmune hemolytic anemia, chronic ITP, Refractory nephrotic syndrome, Refractory SLE, refractory JIA

• Treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in combination with ifosfamide, etoposide, and carboplatin

• Treatment of acquired blood factor deficiency in hemophilia A

• Treatment of steroid-refractory chronic graft-versus-host disease (GVHD)


Contraindications :

Hypersensitivity; Hypersensitive to murine proteins; Caution in elderly pts; Caution if cardiovascular disease or hx, angina or hx, pulmonary disease, high tumor burden, HBV carrier, infection, latent or chronic.


Dosing :

Treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in combination with ifosfamide, etoposide, and carboplatin:

375 mg/sqm IV on days 1 and 3 of cycles 1 and 2, and on day 3 only of cycle 3.

Treatment of steroid-refractory chronic graft-versus-host disease (GVHD):

>8 years-15 years: 375 mg/sqm IV weekly for 4 weeks followed by maintenance therapy with rituximab 375 mg/sqm IV monthly for 4 months.

Refractory autoimmune hemolytic anemia, chronic ITP, Refractory nephrotic syndrome, Refractory SLE, refractory JIA, Treatment of acquired blood factor deficiency in hemophilia A:

375 mg/sqm IV once weekly for 2-4 doses.


Adverse Effect :

Serious Reactions: Mucocutaneous reactions including serious rash such as paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. Anaphylaxis, angioedema, bronchospasm, cardiogenic shock, flushing, hypotension, hypoxia, myocardial infarction, pulmonary infiltrates, throat irritation, tremor, urticaria, and ventricular fibrillation. Acute respiratory distress syndrome and cytokine release syndrome have also been reported. Hepatitis B virus (HBV) reactivation resulting in hepatitis B exacerbation, fulminant hepatitis, hepatic failure, and death. Progressive multifocal leukoencephalopathy (PML), caused by the JC virus.

Common Reactions: infusion reaction, fever/rigors, lymphopenia, infection, Hypogammaglobulinemia, fatigue/asthenia, nausea/vomiting, hypophosphatemia, headache, muscle spasms, night sweats, pruritus/rash/urticaria, insomnia, abdominal pain, leukopenia, neutropenia, cough, thrombocytopenia, epistaxis, diarrhea, dizziness, arthralgia/myalgia, hypotension, hyperglycemia, anemia, peripheral edema, elevated LDH, hypertension.


Interaction :

Interaction Characteristics:
Immunosuppressive effects.
Contraindicated:
Adenovirus vaccine, live; Influenza nasal vaccine, live; Measles/mumps/rubella vaccine, live; Rotavirus vaccine, live; Smallpox vaccine (live vaccinia virus); Typhoid vaccine, live; Varicella vaccine, live; Yellow fever vaccine, live; Zoster vaccine, live.


07/18/2019 09:28:23 Rituximab
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0